Business Wire

Panasonic Develops Drowsiness-Control Technology by Detecting and Predicting Driver's Level of Drowsiness

3.8.2017 07:00 | Business Wire

Jaa

Panasonic Corporation announced today that it has developed a drowsiness-control technology for detecting and predicting a person's level of drowsiness and allowing to stay comfortably awake.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170802006632/en/

Photo1: Detecting drowsiness by observing the blinking features: The system extracts an outline of t ...

Photo1: Detecting drowsiness by observing the blinking features: The system extracts an outline of the eyes and monitors time-sequence shifts in blinking features by checking the opening between the eyelids. (Graphic: Business Wire)

Video available at https://youtu.be/CT4qnpMnrxg

This technology, which can help prevent drowsy driving, detects a driver's shallow drowsiness1 at the initial state by accurately measuring the driver's states without physical contact, including blinking features and facial expressions, etc. captured by an in-vehicle camera, and processing these signals using artificial intelligence. Further, using measurement data from the in-vehicle environment, such as heat loss from the driver and illuminance, Panasonic’s new technology also predicts transitions in the driver's drowsiness level. The technology also combines thermal sensation monitoring function, allowing the driver to stay comfortably awake while driving.

1   Assessed as Level 2 (slightly drowsy) based on the equally spaced five-levels of drowsiness [1]
 

This technology has made it possible to develop a driver-monitoring system that detects the driver's current level of drowsiness and predicts transitions in the driver's drowsiness based on the in-vehicle environment, as well as a drowsiness-control system that allows the driver to stay comfortably awake. These systems prevent the driver from falling asleep while driving.

This new technology offers the following features:

  1. Detects shallow drowsiness the driver is even unaware of by non-contact measurement of blinking features and facial expressions, etc.
  2. Collects in-vehicle environment data to predict transitions in the driver's drowsiness level.
  3. Senses and monitors the driver's level of thermal sensation, allowing the person to stay comfortably awake.

Conventional drowsiness-detection systems had difficulty in predicting transitions in drowsiness. Conventional anti-hypnotic stimulant systems use alarm sounds and vibrations to wake up users, which can make them feel uncomfortable.

Panasonic's newly developed technology, with 22 patents on file, is suitable for applications in human- and environment-monitoring systems for use in such places as private and commercial vehicles, offices and educational institutions; drowsiness-prediction systems; and drowsiness-control systems for keeping people awake.

Key Technological Features:

1. Detects shallow drowsiness the driver is even unaware of by non-contact measurement of blinking features and facial expressions, etc.

A person who feels drowsy shows various signs. For example, people will "have a drowsy facial expression," or "blink in a specific way," when becoming drowsy. Identifying these signs allows to detect the level of drowsiness.

Utilizing image recognition technologies refined through the development of monitoring cameras and other systems, Panasonic has recently developed non-contact and highly accurate technology for detecting people's blinking features and facial expressions, etc. from photographed images. The company has also compiled a database of various measurements on drowsiness and biological signals, and analyzed, from a physiological standpoint, the relationship between about 1,800 parameters related to blinking features and facial expressions, etc., and drowsiness that were extracted from the database. Based on the results of an analysis of drowsy expressions compiled during joint research with the Ohara Memorial Institute for Science of Labour, a public interest foundation, Panasonic has developed an artificial intelligence capable of estimating an individual's drowsiness level.

These achievements allow to detect the signs of shallow drowsiness, even if a person is not aware of it, and to identify the actual level of drowsiness.

2. Collects in-vehicle environment data to predict transitions in the driver's drowsiness level

Generally, people rarely become drowsy in a cool and bright environment, but can easily become drowsy in a warm and dim environment. Therefore, it is assumed that drowsiness depends on in-vehicle environmental factors, such as temperature and brightness. However, some people wear a lot of clothes while others wear less at the same temperature. Such variations in human behavior make it difficult to estimate people's drowsiness based only on the ambient temperature.

Panasonic has conducted joint research with Chiba University, which revealed that heat loss from a person's body is correlated with the person's drowsiness after prescribed time elapses, regardless of how much clothes the person wears. Panasonic has also developed a contactless technology to measure heat loss from a person's body with the company’s original infrared array sensor Grid-EYE [2]. In addition, the company has identified the effect of the elapsed time and the surrounding brightness, which is measured by an environment sensor, on a person's level of drowsiness.

These results have made it possible to predict how a person's current drowsiness can change by means of heat loss from the body (measured without contact) and the surrounding brightness.

3. Senses and monitors the driver's level of thermal sensation, allowing the person to stay comfortably awake

Adjusting room temperature or airflow based on an individual's estimated level of drowsiness makes it easier to keep a person awake. However, a person would feel a cold when the room temperature is too low, which the level of thermal comfort would be disturbed. By applying our knowledge of thermal environments and physiology accumulated through research & development of indoor air conditioners and other products, Panasonic has developed, through joint research with Nara Women's University, a technology to estimate the thermal sensation2. This technology can be used inside a vehicle, where the effects of airflow and others are significant. By applying the infrared array sensor Grid-EYE, an individual's level of thermal sensation can be constantly monitored as an optimum means of controlling temperature, for example, an air conditioner. This allows a person to stay comfortably awake3.

2   Technology using an infrared array sensor to detect a person's level of thermal sensation (sensing of warm and cold) without contact.
3 When a driver's current drowsiness level is detected as high, a sound alarm or a command to rest is issued.
 

Terms

[1] Equally spaced five levels of drowsiness
Scale for determining the level of a person's drowsiness from the facial expression. The drowsiness levels are assessed into following five levels: 1. Not drowsy at all, 2. Slightly drowsy, 3. Drowsy, 4. Very drowsy, 5. Seriously drowsy.
Source: Hiroki Kitajima, Nakaho Numata, Keiichi Yamamoto, Yoshihiro Goi: "Prediction of Automobile Driver sleepiness (1st Report, Rating of Sleepiness Based on Facial Expression and Examination of Effective Predictor Indexes of Sleepiness)," Transactions of the Japan Society of Mechanical Engineers (C edition), Vol. 63, No. 613, pp. 93–100, 1997.

[2] Infrared array sensor Grid-EYE
The infrared array sensor carries two-dimensionally arranged pixels that detect infrared rays (wavelength: 10 µm) emitted from a human body or object. It is capable of measuring a two-dimensional temperature distribution. Panasonic’s infrared array sensor Grid-EYE has 64 pixels. Equipped with a super-resolution algorithm and can be swung with appropriate speed and an angle, thus offering clear thermal images equivalent in resolution to images created with about 7,800 pixels.

About Panasonic

Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. Celebrating its 100th anniversary in 2018, the company has expanded globally and now operates 495 subsidiaries and 91 associated companies worldwide, recording consolidated net sales of 7.343 trillion yen for the year ended March 31, 2017. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: http://www.panasonic.com/global.

Contact information

Media Contact:
Global Communications Department
Panasonic Corporation
http://news.panasonic.com/global/contacts/

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 16:25Tiedote

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the

IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 15:00Tiedote

IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman

PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 11:03Tiedote

PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate

Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 11:00Tiedote

Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The

Boehringer Ingelheim: Advancing anticoagulation care with new data at ESC Congress 201721.8.2017 10:08Tiedote

Boehringer Ingelheim today announced that it will present important new data on the treatment of patients with atrial fibrillation (AF) at the ESC Congress in Barcelona, Spain, 26-30 August 2017. In total, four abstracts have been accepted, investigating different aspects of AF patient treatment. The results of the RE-DUAL PCI™ trial have been selected for one of the Late Breaking Science sessions of the congress. The RE-DUAL PCI™ trial compared dual therapy with triple therapy after percutaneous coronary intervention (PCI) with stent placement in approximately 2,500 adults with atrial fibrillation. Patients were either treated with dabigatran etexilate (Pradaxa®) and a single antiplatelet agent or with the vitamin K antagonist (VKA) warfarin and two antiplatelets. The dabigatran doses investigated in this trial are the same doses which have already demonstrated effective stroke preven

Study Investigates Performance of Masimo PVi® As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery21.8.2017 09:00Tiedote

Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Firat University in Turkey evaluated the performance of Masimo PVi®, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during respiratory cycles, as the basis of a goal-directed fluid therapy (GDFT) protocol during laparoscopic bariatric surgery on mechanically-ventilated patients.1 In the study, Dr. Demirel and colleagues sought to evaluate whether using GDFT guided by PVi on morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) surgery might result in less intravenous fluid use without compromising outcomes. They enrolled 60 patients and divided them randomly into control and GDFT groups. The control group’s fluid levels were managed by standard fluid therapy, using mean arterial pressure (MAP) and

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme